Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Neoadjuvant chemotherapy can improve the survival of individuals with borderline and
unresectable pancreatic ductal adenocarcinoma; however, heterogeneous responses to …

Patients with pancreatic ductal adenocarcinoma (PDAC) usually have a dismal prognosis,
and even after curative resection most patients will have disease relapse and ultimately die …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …

Importance Preoperative chemo (radio) therapy is increasingly used in patients with
localized pancreatic adenocarcinoma, leading to pathological complete response (pCR) in a …

Background The role of postoperative chemotherapy in patients with resected pancreatic
cancer who receive neoadjuvant treatment is unknown. Clinicians use changes in CA19-9 …

Abstract Background Cancer antigen 19-9 (CA19-9) is widely used as a marker of
pancreatic cancer tumor burden and response to therapy. Synthesis of CA19-9 and its …

Background Tumor fibrosis after neoadjuvant treatment (NAT) for pancreatic ductal
adenocarcinoma (PDAC) correlates with treatment response. Herein we assessed how …

Aims Following the increased use of neoadjuvant therapy for pancreatic cancer, grading of
tumour regression (TR) has become part of routine diagnostics. However, it suffers from …